CoChat

The risk predictive values of UK‐PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti‐gp210

Open access
Yang, F., Yang, Y., Wang, Q., Wang, Z., Miao, Q., Xiao, X., Wei, Y., Bian, Z., Sheng, L., Chen, X., Qiu, D., Fang, J., Tang, R., Gershwin, M. E., Ma, X. · 2017 · Alimentary Pharmacology & Therapeutics
Cited by 89

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Summary: Background: Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis (PBC). The UK‐PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population. Aim: To validate the UK‐PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti‐gp210 as a biomarker, and to investigate whether anti‐gp210 could affect the prognostic values of UK‐PBC and GLOBE scoring systems. Methods: We retrospectively analysed 276 patients with PBC evaluated between September 2004 and May 2016, including 133 anti‐gp210+ and 143 anti‐gp210− patients. Results: The 5‐year adverse outcome‐free survivals of anti‐gp210+ vs. anti‐gp210− patients were 70% and 85%, respectively (P = 0.005). Cirrhosis (P = 0.001), albumin level ≤40 g/L (P = 0.011) and platelet count ≤153 × 10 9 (P < 0.001) had a superimposition effect on anti‐gp210 antibody as a risk factor. Furthermore, long‐term prognoses were evaluated using the UK‐PBC and GLOBE scores. For UK‐PBC scoring system, the area under receiver operating characteristic curve (AUROC) was 0.924 for all patients with PBC (n = 223), 0.940 for anti‐gp210+ patients (n = 110) and 0.888 for anti‐gp210− patients (n = 113). For GLOBE scoring system, the area under receiver operating characteristic curve was 0.901 for all patients with PBC (n = 223), 0.924 for anti‐gp210+ patients (n = 110) and 0.848 for anti‐gp210− patients (n = 113). UK‐PBC score >0.0578 (P < 0.001, HR: 32.736, 95% CI: 11.368–94.267) and GLOBE score <0.850 (P < 0.001, HR: 18.763, 95% CI: 7.968–44.180) were associated with poorer outcomes in the whole cohort. Conclusions: The UK‐PBC and GLOBE scoring systems were good 5‐year prognostic predictors in Chinese patients with PBC, especially in anti‐gp210+ patients. As a biomarker, anti‐gp210 antibody was associated with a more severe cholestatic manifestation and a worse long‐term prognosis. The anti‐gp210 antibody could be added to further optimise the UK‐PBC and GLOBE scoring systems.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.13927

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

Metadata

Authors
Yang, F., Yang, Y., Wang, Q., Wang, Z., Miao, Q., Xiao, X., Wei, Y., Bian, Z., Sheng, L., Chen, X., Qiu, D., Fang, J., Tang, R., Gershwin, M. E., & Ma, X.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2017-01-13
Volume
45
Issue
5
Pages
733-743
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2575398213
Cited by
89
References
15
FWCI
5.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.